InflaRx (IFRX) FDA Approvals

InflaRx logo
$1.10 -0.06 (-4.78%)
As of 12:59 PM Eastern
This is a fair market value price provided by Massive. Learn more.

InflaRx's Drugs in the FDA Approval Process

This section highlights FDA-related milestones and regulatory updates for drugs developed by InflaRx (IFRX). Over the past two years, InflaRx has reported clinical trial outcomes, regulatory submissions, approvals, and other FDA events for drugs and therapies such as Izicopan, Vilobelimab, and INF904. For definitions of regulatory abbreviations such as NDA, BLA, or PDUFA, see the event status legend. Select a button below to view the list of FDA events for that drug.

Izicopan FDA Regulatory Timeline and Events

Izicopan is a drug developed by InflaRx for the following indication: small molecule inhibitor of the C5a receptor (C5aR). This drug is under review by the U.S. Food and Drug Administration (FDA). Below is a timeline of key regulatory milestones for this therapy.

Vilobelimab FDA Regulatory Timeline and Events

Vilobelimab is a drug developed by InflaRx for the following indication: Pyoderma Gangraenosum. This drug is under review by the U.S. Food and Drug Administration (FDA). Below is a timeline of key regulatory milestones for this therapy.

INF904 FDA Regulatory Events

INF904 is a drug developed by InflaRx for the following indication: C5aR Inhibitor. This drug is under review by the U.S. Food and Drug Administration (FDA). Below is a timeline of key regulatory milestones for this therapy.

InflaRx FDA Events - Frequently Asked Questions

In the past two years, InflaRx (IFRX) has not received FDA approval for any therapies. However, the company does have drugs under review or in active clinical development.

In the past two years, InflaRx (IFRX) has reported FDA regulatory activity for the following drugs: Vilobelimab, Izicopan and INF904.

The most recent FDA-related event for InflaRx occurred on November 6, 2026, involving Izicopan. The update was categorized as "Peer-reviewed publication," with the company reporting: "InflaRx N.V. announced the peer-reviewed publication of first-in-human Phase 1 clinical data for izicopan, formerly known as INF904, the Company’s orally administered, next-generation small molecule inhibitor of the C5a receptor (C5aR1)."

Current therapies from InflaRx in review with the FDA target conditions such as:

  • Pyoderma Gangraenosum - Vilobelimab
  • small molecule inhibitor of the C5a receptor (C5aR) - Izicopan
  • C5aR Inhibitor - INF904
  • NDA: New Drug Application
  • ANDA: Abbreviated New Drug Application
  • sNDA: Supplemental New Drug Application
  • BLA: Biologics License Application
  • sBLA: Supplemental Biologics License Application
  • FDA Approved: Approved by the FDA
  • EMA: European Medicines Agency
  • CE Mark: European Union Certification
  • NMPA: China National Medical Products Administration
  • MHLW: Japanese Ministry of Health
  • FDA Meeting: Consultation with FDA
  • Pre-IND: Pre-Investigational New Drug Meeting
  • Breakthrough Therapy: Special FDA designation for promising therapies
  • Fast Track: Accelerated FDA approval pathway
  • Orphan Drug: Designation for rare disease treatments
  • RPD: Rare Pediatric Disease Designation
  • RMAT: Regenerative Medicine Advanced Therapy
  • DSMB Review: Data Safety Monitoring Board Review
  • IDMC Review: Independent Data Monitoring Committee
  • MAA: MHRA Marketing Authorization Application
  • RTF: Refusal to File (Rejected Application)
  • 510(k): FDA Clearance for Medical Devices
  • Rolling Submission: Staggered regulatory review process

FDA progress for NASDAQ:IFRX last updated on 11/6/2026 by MarketBeat.com Staff. We continuously monitor for new FDA events and market data.
From Our Partners